Business Wire

A Momentous 2023, Headlined by a 19% increase of ARR, Positions Percona for Even Greater Success in the Year Ahead

27.3.2024 16:00:00 EET | Business Wire | Press release

Share

Percona, a leader in enterprise-grade, open source database software, support, and services, has entered 2024 fresh off a year marked by sustained customer growth, multiple prestigious award wins, and innovative product enhancements. The company's impressive 2023 has further solidified its standing as a go-to provider of open source database solutions and support services.

Having predicted the database market to clear $100 billion in 2023, Gartner forecasts the market to grow at a compound annual growth rate (CAGR) of 16.8% through 2027 and reach $203.6 billion. This underscores sustained demand for sophisticated database management expertise to ensure optimal performance, security, and reliability. Uniquely qualified to address these needs, Percona has capitalized on the expanding opportunity, realizing a 19% increase in Annual Recurring Revenue (ARR).

Customer-Led Growth

Fueled by ongoing innovation and an unwavering commitment to customer success, Percona has continued to broaden its customer base — with both new customer acquisitions and expanded relationships with existing customers contributing to its fully organic growth.

One notable example, EveryMatrix, a prominent iGaming software provider, has benefited from Percona's managed services expertise, optimizing their database management for MySQL, MariaDB, and PostgreSQL. This collaboration has resulted in enhanced database performance, resilience, and security, empowering EveryMatrix to focus on innovation and customer satisfaction within the highly competitive online gaming industry.

Similarly, PagerDuty relies on Percona's support for MySQL, ensuring reliable and high-performance database instances critical to PagerDuty's operations. Percona's proactive assistance, including end-of-life support for MySQL 5.7 and migration planning, underscores its commitment to delivering exceptional support and expertise to its clientele.

2023 also saw some of the world’s most recognizable brands signing on with Percona or expanding the scope of their engagement. Percona began supporting companies such as Netflix and the United States Geological Survey. The company expanded its scope further by partnering with Merchant Warrior, Otto Office, and Kontron, among others.

Awards and Recognition

Percona’s track record as a leader in the open source database community yielded several prestigious awards and acknowledgments in 2023.

Most recently, the company secured the title of "Best DevOps for DataOps/Database Solution" at the Devops Dozen awards, illustrating its commitment to delivering cutting-edge solutions tailored to modern DevOps practices. Additionally, Percona's innovative products have been featured among the trend-setting products in data and information management for 2024 by DBTA (Database Trends and Applications), further validating its position as an industry trailblazer.

Moreover, Percona thought leaders like CEO Ann Schlemmer and Technology Evangelist Dave Stokes have garnered attention in publications such as Forbes, Computer Weekly, InfoWorld, The New Stack, The Register, and more. In these thought pieces Percona’s leaders have spearheaded discussions on data and open source, shaping the discourse around emerging trends and best practices.

Innovations and Enhancements

Percona continued to push the boundaries of database innovation with the recent Beta release of Percona Everest, an open source cloud-native database platform. Percona Everest is the first open source solution that combines multi-cloud and multi-database capabilities in one platform. With an intuitive user interface (UI) and command-line interface (CLI), Percona Everest offers advanced database provisioning and management features at no cost while providing control over infrastructure expenses, eliminating vendor lock-in.

Percona Everest allows users to enjoy flexible features such as provisioning, scalability, performance optimization, and high availability with full automation. By integrating with Kubernetes Operators, Percona Everest empowers users to run databases anywhere, liberating them from the constraints of public cloud platforms.

In addition to the Beta release of Percona Everest, Percona introduced numerous enhancements and updates to its product lineup over the course of 2023, including:

  • A complete post-EOL support program for MySQL 5.7, which allows participating customers to continue to operate on a fully supported Percona Server for MySQL 5.7 until upgrading to later major versions becomes more convenient. Within this program, Percona continues to release the CVE-patched versions of MySQL 5.7 to participating customers.
  • Percona Monitoring and Management (PMM) introduced MongoDB backup monitoring capabilities, which provide users with a streamlined backup and restore process and improved inventory management.

Primed for Growth

Looking ahead, Percona is poised for continued expansion. The company remains steadfast in its mission to make enterprise databases run better through a unique blend of expertise and open source software.

"As we reflect on our recent achievements and the strides we've made in 2023, it's clear that all the attributes customers value in a vendor – dedication to innovation, customer-centric solutions, and fostering meaningful relationships – are moving Percona in the right direction," said Ann Schlemmer, CEO of Percona. "We are proud of each milestone we’ve reached and the incredible team that has gotten us here, and we look forward to continuing our commitment to driving progress."

Percona will reaffirm its leadership within the open source database community by participating in key industry events throughout 2024, including KubeCon North America and Open Source Summit North America. At these events, and many others, Percona will continue to expand its impact on the open source database community.

Learn more about how databases perform better with Percona.

About Percona:

Percona is a world-class open source database software, support, and services company. The organization is dedicated to helping businesses ensure their databases — and the applications that depend on them — are secure, compliant, performant, and highly available.

Through a unique combination of database expertise and enterprise-grade open source software, Percona empowers organizations with the freedom to choose, the freedom to create, and the freedom to innovate with speed as they grow. For more information, visit www.percona.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jacob Manchester
Senior Account Executive, PR
Scratch Marketing + Media
Percona@scratchmm.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye